Abstract
Chemokine are small, inducible pro-inflammatory cytokines involved in many biological processes, such as migration of leukocytes, atherosclerosis, angiogenesis, tumor growth, and metastasis. Chemokine are also known to influence tumor cell’s activity. Specifically, tumor cells express chemokine receptors in a non random manner suggesting a role of chemokine in metastatic destination of tumor cells. The present study was conducted to determine distribution of (Chemokine receptor 2) CCR2 V64I, Chemokine ligand 2 CCL2 I/D, and CCL2 2518 A>G gene polymorphisms in North Indian population and compare with different populations globally. Polymerase chain reaction (PCR)-based analysis was conducted in 200 normal healthy individuals of similar ethnicity. Allelic frequencies in wild type (GG) of CCR2 V64I G>A were 63 % G; CCL2 I/D 42 % II; CCL2 2518 A>G 40.5 % A. The minor variant allele frequency in our population was as follows: 19.5 % for CCR2 V64I, 35.5 % for CCL2 I/D, 35.3 % for CCL2 2518 A>G. We further compared frequency distribution for these genes with various published studies in different ethnicity. Our results suggested that frequency in chemokine genes exhibit distinctive pattern in India that could be attributed to ethnicity variation. This could assist in high-risk screening of human exposed to environmental carcinogens and cancer predisposition in different ethnic groups. Thus, they signify an impact of ethnicity and provide a basis for future epidemiological and clinical studies.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Zlotnik A, Yoshie O, Nomiyama H. The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biol. 2006;7(12):243.
Raman D, Baugher PJ, Thu YM, Richmond A. Role of chemokines in tumor growth. Cancer Lett. 2007;256(2):137–65.
Lazennec G, Richmond A. Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med. 2010;16(3):133–44.
Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol. 2010;22(2):231–7.
Rovin BH, Lu L, Saxena R. A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun. 1999;259(2):344–8.
Nakayama EE, Tanaka Y, Nagai Y, Iwamoto A, Shioda T. A CCR2-V64I polymorphism affects stability of CCR2A isoform. AIDS. 2004;18(5):729–38.
Zhang J, Patel L, Pienta KJ. CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev. 2010;21(1):41–8.
Fidler IJ. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer. 2003;3(6):453–8.
Gupta GP, Massagué J. Cancer metastasis: building a framework. Cell. 2006;127(4):679–95.
Ye S. Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol. 2000;19(7):623–9.
Hynes RO. Metastatic potential: generic predisposition of the primary tumor or rare, metastatic variants—or both? Cell. 2003;113(7):821–3.
Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16(3):1215.
Ahluwalia TS, Khullar M, Ahuja M, Kohli HS, Bhansali A, Mohan V, et al. Common variants of inflammatory cytokine genes are associated with risk of nephropathy in type 2 diabetes among Asian Indians. PLoS ONE. 2009;4(4):e5168.
Narter KF, Agachan B, Sozen S, Cincin ZB, Isbir T. CCR2-64I is a risk factor for development of bladder cancer. Genet Mol Res. 2010;9(2):685–92.
Kittles RA, Weiss KM. Race, ancestry, and genes: implications for defining disease risk. Annu Rev Genomics Hum Genet. 2003;4:33–67.
Chatterjee K, Dandara C, Hoffman M, Williamson AL. CCR2-V64I polymorphism is associated with increased risk of cervical cancer but not with HPV infection or pre-cancerous lesions in African women. BMC Cancer. 2010;10:278.
Alagarasu K, Selvaraj P, Swaminathan S, Raghavan S, Narendran G, Narayanan PR. CCR2, MCP-1, SDF-1a and DC-SIGN gene polymorphisms in HIV-1 infected patients with and without tuberculosis. Indian J Med Res. 2009;130(4):444–50.
Kruszyna L, Lianeri M, Rubis B, Knuła H, Rybczyńska M, Grodecka-Gazdecka S, et al. CCL2 -2518 A/G single nucleotide polymorphism as a risk factor for breast cancer. Mol Biol Rep. 2011;38(2):1263–7.
Singh R, Kapoor R, Srivastava A, Mittal RD. Impact of chemokine receptor CCR2 and CCR5 gene polymorphism on allograft outcome in North Indian renal transplant recipients. Scand J Immunol. 2009;69(1):51–6.
Prasad P, Tiwari AK, Kumar KM, Ammini AC, Gupta A, Gupta R, et al. Association of TGFbeta1, TNFalpha, CCR2 and CCR5 gene polymorphisms in type-2 diabetes and renal insufficiency among Asian Indians. BMC Med Genet. 2007;8:20.
Zheng B, Wiklund F, Gharizadeh B, Sadat M, Gambelunghe G, Hallmans G, et al. Genetic polymorphism of chemokine receptors CCR2 and CCR5 in Swedish cervical cancer patients. Anticancer Res. 2006;26(5B):3669–74.
Petrkova J, Cermakova Z, Drabek J, Lukl J, Petrek M. CC chemokine receptor (CCR)2 polymorphism in Czech patients with myocardial infarction. Immunol Lett. 2003;88(1):53–5.
Hizawa N, Yamaguchi E, Furuya K, Jinushi E, Ito A, Kawakami Y. The role of the C–C chemokine receptor 2 gene polymorphism V64I (CCR2-64I) in sarcoidosis in a Japanese population. Am J Respir Crit Care Med. 1999;159(6):2021–3.
Manchanda PK, Singh R, Mittal RD. Cytokine (IL-10 -1082 and -819) and chemokine receptor (CCR2 and CCR5) gene polymorphism in North Indian patients with end-stage renal disease. DNA Cell Biol. 2009;28(4):177–83.
Bektas-Kayhan K, Unur M, Boy-Metin Z, Cakmakoglu B. MCP-1 and CCR2 gene variants in oral squamous cell carcinoma. Oral Dis. 2012;18(1):55–9.
Chinoy H, Salway F, Fertig N, Tait BD, Oddis CV, Ollier WE, et al. Monocyte chemotactic protein-1 single nucleotide polymorphisms do not confer susceptibility for the development of adult onset polymyositis/dermatomyositis in UK Caucasians. Rheumatology. 2007;46(4):604–7.
Steinmetz OM, Panzer U, Harendza S, Mertens PR, Ostendorf T, Floege J, et al. No association of the -2518 MCP-1 A/G promoter polymorphism with incidence and clinical course of IgA nephropathy. Nephrol Dial Transplant. 2004;19(3):596–601.
Buraczynska M, Bednarek-Skublewska A, Buraczynska K, Ksiazek A. Monocyte chemoattractant protein-1 (MCP-1) gene polymorphism as a potential risk factor for cardiovascular disease in hemodialyzed patients. Cytokine. 2008;44(3):361–5.
Acknowledgments
We are thankful to DBT (Department of Biotechnology, New Delhi) and ICMR (Indian Council of Medical Research, New Delhi) for providing financial support for the study. We are also thankful to the volunteers for providing the blood samples.
Conflict of interest
There is no conflict of interest among the authors.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Singh, V., Srivastava, N., Srivastava, P. et al. Impact of CCL2 and Its Receptor CCR2 Gene Polymorphism in North Indian Population: A Comparative Study in Different Ethnic Groups Worldwide. Ind J Clin Biochem 28, 259–264 (2013). https://doi.org/10.1007/s12291-012-0265-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12291-012-0265-0